Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Annals of the Rheumatic Diseases|June 28, 2018
Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosusPeter H Schafer, Ying Ye, Lei Wu, et al.
Cellular Immunology|December 16, 2004
Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent mannerFaribourz Payvandi, Lei Wu, Maura Haley, et al.
Journal of Translational Medicine|July 21, 2007
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanomaDavid P Mangiameli, Joseph A Blansfield, Stephan Kachala, et al.
Journal of Drugs in Dermatology : JDD|August 30, 2013
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label studyAlice B Gottlieb, Robert T Matheson, Alan Menter, et al.
Lupus Science & Medicine|February 16, 2022
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a studyRichard A Furie, Douglas R Hough, Allison Gaudy, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|January 16, 2024
Circulating biomarker analyses in a longitudinal cohort of patients with IPFChristina Ebert, Alice M Walsh, Larisa Sereda, et al.
The Journal of Surgical Research|September 4, 2009
CC-5079: a small molecule with MKP1, antiangiogenic, and antitumor activityHuan N Vu, Walter J Miller, Sarah A O'Connor, et al.
Cellular Signalling|January 26, 2016
Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complexPeter H Schafer, Francesca Truzzi, Anastasia Parton, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|October 26, 2005
Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-theta activation and enhancing the DNA-binding activity of AP-1 but not NF-kappaB, OCT-1, or NF-ATFaribourz Payvandi, Lei Wu, Syedah D Naziruddin, et al.
Journal of the American Academy of Dermatology|October 26, 2024
Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: A randomized phase 2 clinical trialVictoria P Werth, Joan T Merrill, Richard Furie, et al.
Pageof 5